Mary Reumuth
Director of Finance/CFO at KALA BIO, INC.
Net worth: 462 797 $ as of 2024-04-29
Mary Reumuth active positions
Companies | Position | Start | End |
---|---|---|---|
KALA BIO, INC. | Comptroller/Controller/Auditor | 2014-01-31 | - |
Director of Finance/CFO | 2014-01-31 | - | |
Treasurer | 2014-01-31 | 2017-06-30 | |
OLINK HOLDING AB | Director/Board Member | 2022-04-06 | - |
Independent Dir/Board Member | 2022-04-06 | - |
Career history of Mary Reumuth
Former positions of Mary Reumuth
Companies | Position | Start | End |
---|---|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Comptroller/Controller/Auditor | 2011-04-30 | 2012-05-31 |
VERENIUM CORP | Director of Finance/CFO | 2007-11-30 | 2011-02-28 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Training of Mary Reumuth
Texas A&M University | Undergraduate Degree |
Statistics
International
United States | 5 |
Canada | 2 |
United Kingdom | 2 |
Operational
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 2 |
Corporate Officer/Principal | 2 |
Sectoral
Health Technology | 6 |
Commercial Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
KALA BIO, INC. | Health Technology |
OLINK HOLDING AB | Health Technology |
Private companies | 4 |
---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Verenium Corp.
Verenium Corp. BiotechnologyHealth Technology Verenium Corp. produces cellulosic ethanol derived from multiple biomass feedstocks. It manufactures and markets enzyme products in the fields of animal health and nutrition, grain processing, oilseed processing, oilfield services and other industrial processes such as pulp and paper and textiles. The company was founded in December 1992 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Mary Reumuth
- Experience